🇺🇸 NPL insulin in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypertension — 2 reports (18.18%)
  2. Aphasia — 1 report (9.09%)
  3. Asthenia — 1 report (9.09%)
  4. Atrial Fibrillation — 1 report (9.09%)
  5. Bacterial Infection — 1 report (9.09%)
  6. Cardiovascular Disorder — 1 report (9.09%)
  7. Cataract — 1 report (9.09%)
  8. Cerebrovascular Accident — 1 report (9.09%)
  9. Diabetic Gastroparesis — 1 report (9.09%)
  10. Diabetic Neuropathy — 1 report (9.09%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is NPL insulin approved in United States?

NPL insulin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NPL insulin in United States?

University of Campania Luigi Vanvitelli is the originator. The local marketing authorisation holder may differ — check the official source linked above.